In a patient on antiplatelet medication involved in a road‑traffic accident with no evidence of head injury and no symptoms (no headache, vomiting, confusion, focal deficit, or loss of consciousness), is a non‑contrast head CT required or can the patient be safely discharged after brief observation?

Management of Antiplatelet Patients After Road Traffic Accident Without Head Injury or Symptoms

In a patient on antiplatelet medication involved in a road-traffic accident with no evidence of head injury and no symptoms, a head CT is NOT required and the patient can be safely discharged immediately without observation. 1

Clinical Reasoning

The 2023 ACEP Clinical Policy provides clear guidance for this exact scenario. The key distinction here is that your patient has:

• No head injury (no trauma above the clavicles)
• No symptoms (no headache, vomiting, confusion, focal deficits, or loss of consciousness)
• GCS of 15 (implied by being asymptomatic)

Why No CT is Needed

The ACEP guidelines specifically address patients who did sustain head trauma and found that even in those cases, neurologically intact patients on antiplatelet agents can be safely discharged after a normal initial CT 1. Your patient has an even lower risk profile because:

1. No mechanism of head injury occurred - The guidelines apply to patients with confirmed blunt head trauma, which your patient lacks
2. Complete absence of symptoms - The guidelines show delayed intracranial hemorrhage (ICH) is rare (0.6-1.5%) even in symptomatic patients with documented head trauma 1
3. No high-risk features - The patient lacks all concerning features: no loss of consciousness, no amnesia, no neurological findings, GCS 15 1

Evidence Base

The strongest evidence comes from the multicenter Nishijima study (Class II), which followed 1,064 patients with actual blunt head trauma on anticoagulants/antiplatelets. Even in this higher-risk population with confirmed trauma, delayed ICH was extremely rare (0.6% for warfarin, 0% for clopidogrel) 1. Recent 2026 data from 5,800 patients with minimal head injury showed only 0.2% developed delayed ICH, with none requiring neurosurgical intervention 2.

Important Caveats

The aspirin exception: If your patient is elderly (≥65 years) on aspirin specifically, there is slightly more caution warranted. One study showed 4% delayed ICH rate in elderly aspirin users, though this was in patients who had sustained head trauma 1. Your patient without any head injury falls well below this risk threshold.

What constitutes "no head injury": Ensure there is truly no trauma above the clavicles - no scalp laceration, no palpable hematoma, no tenderness, no visible contusion. If any physical evidence of head impact exists, this changes the risk stratification entirely 3.

Discharge Protocol

Since no imaging or observation is required, proceed with immediate discharge including:

• Clear return precautions: Instruct to return immediately for new headache, vomiting, confusion, vision changes, weakness, or seizures
• Continue antiplatelet medication: No need to hold aspirin, clopidogrel, or other antiplatelet agents 1
• Ensure adequate support: Patient should have someone available to monitor them at home for the first 24 hours, though clinical deterioration is exceedingly unlikely 1

Common Pitfalls to Avoid

1. Over-imaging based on medication alone: Antiplatelet therapy is not an indication for CT in the absence of head trauma or symptoms 2, 4
2. Unnecessary observation: Even in patients with confirmed mild head trauma and normal CT, observation adds no clinical benefit 1
3. Confusing antiplatelet with anticoagulant risk: While warfarin carries higher ICH risk (3.9% vs 1.5% in non-anticoagulated patients), this applies only to those with actual head trauma 1

Bottom line: Your patient requires neither CT imaging nor observation. Document the absence of head injury mechanism, the lack of symptoms, and provide standard discharge instructions. This approach is supported by the highest quality 2023 guidelines and prioritizes avoiding unnecessary radiation exposure and healthcare costs while maintaining patient safety 1, 2, 4.